Antibody-Drug Conjugates in Advanced Lung Cancer: Is This a New Frontier?

Abstract: Over the past decade, the lung cancer landscape has been dominated by targeted and immunotherapeutic approaches that have drastically shifted treatment paradigms for patients with […]

Redefining the Standard of Care for Low-Grade Serous Ovarian Cancer

Abstract: Low-grade serous carcinoma is a rare epithelial ovarian cancer subtype with distinct clinical, histologic, and molecular features. Improved understanding of this disease subtype has prompted […]

Immune Checkpoint Inhibitor Therapy in Locally Advanced MSI GI Malignancies

Abstract: Locally advanced gastrointestinal (GI) malignancies have conventionally been treated in a multimodal fashion that combines (neo)adjuvant chemotherapy with or without radiation and definitive surgical resection. […]

Increasing Inclusion and Equity for Black Women in Breast Cancer Clinical Trials

Abstract: Black women diagnosed with breast cancer experience a disproportionately high mortality rate. The disparity in outcomes between Black and White women is multifactorial, with a […]

The Role of Noncovalent BTK Inhibitors in the Era of Covalent BTK Inhibitors

Abstract: Despite significantly improving outcomes in patients with B-cell malignancies, covalent Bruton tyrosine kinase (BTK) inhibitors are limited by toxicities and the development of resistance. Some […]

Immunotherapy in the Treatment of Advanced or Recurrent Endometrial Cancer

Abstract: The standard treatment of patients with advanced or recurrent endometrial cancer has not significantly changed over the past few decades, reflecting a major unmet clinical […]

Management of KRAS-Mutated Non–Small Cell Lung Cancer

Abstract: Kirsten rat sarcoma virus (KRAS) is the most frequently mutated oncogene in human cancers, particularly in non–small cell lung cancer (NSCLC), where mutations are present […]

Recombinant Interferon Alfa in BCR/ABL-Negative Chronic Myeloproliferative Neoplasms

Abstract: The treatment landscape for BCR/ABL-negative myeloproliferative neoplasms (MPNs), driven by JAK2, CALR, and MPL mutations, has evolved significantly over the last decade. Recent regulatory approvals […]

Evolving Applications of Liquid Biopsies in Gastrointestinal Cancers

Abstract: Liquid biopsy is a test that allows for the diagnosis and analysis of cancer by sampling cancer cells or byproducts present in biological fluids such […]

Risk Factors for Disease Progression and Treatment Goals in Polycythemia Vera

Abstract: Polycythemia vera is a Philadelphia chromosome–negative myeloproliferative neoplasm characterized by the clonal proliferation of hematopoietic cells, leading to the overproduction of erythrocytes and the elaboration […]

Addressing Unmet Need in the Management of Patients With ER+/HER2–, ESR1-Mutated Metastatic Breast Cancer: Clinician’s Perspective

Abstract: Approximately 70% of breast tumors are ER+ and HER2–. First-line treatment that combines endocrine therapy (AIs, SERMs, and SERDs) with a CDK4/6 inhibitor is the […]

Novel Combination Approaches to Locoregional and Systemic Therapy in the Management of Primary and Metastatic Liver Tumors

Abstract: Several pathways and mutations must develop or be in place for the onset of cancer. Therefore, therapies should ideally target as many of these pathways […]

Overcoming the Hurdles: Surmounting Acquired Resistance to Anti-EGFR Therapy in Metastatic Colorectal Cancer

Abstract: Colorectal cancer is the third most prevalent cancer type in the United States, with an alarming incidence and mortality rate, especially among individuals younger than […]

Surgical Resection Criteria and Neoadjuvant Therapies for Intrahepatic Cholangiocarcinoma

Abstract: The staging of intrahepatic cholangiocarcinoma (ICC) is complex, and there is no consensus among international cancer groups on how to most appropriately select candidates with […]

Reappraisal of Cardiovascular Risk Factors in Patients With Chronic Myeloproliferative Neoplasms

Abstract: Cardiovascular (CV) risk factors are important contributors to thrombotic risk in the general population and in patients with chronic myeloproliferative neoplasms (MPNs). However, the role […]

The Use of Positron Emission Tomography Imaging to Guide Radiation Therapy

Abstract: Positron emission tomography (PET)-based biologic radiation planning has the potential to improve tumor control by improving the accuracy of radiation delivery, allow for rational adaptive […]

Selecting the Optimal Radiation Modality in Prostate Cancer

Abstract: There are numerous radiation modalities for the definitive treatment of localized prostate cancer. Classic clinical trials have established the basic tenets of treatment approaches, and […]

Predicting Outcomes and Monitoring Disease in Patients With Multiple Myeloma

Abstract: Multiple myeloma (MM) is a clonal plasma cell dyscrasia and the most common form of primary bone marrow cancer. Nearly 35,000 new cases of MM […]

Acral Melanoma: Clinical Advances and Hope for the Future

Abstract: Acral melanoma is a rare subtype of melanoma with unique histologic and biologic characteristics. Given its relative rarity compared with nonacral cutaneous melanoma, acral melanoma […]

Neoadjuvant Immunotherapy in Resectable Non–Small Cell Lung Cancer

Abstract: Lung cancer is the leading cause of cancer-related deaths worldwide and is associated with poor 5-year outcomes, even among the 20% to 25% of patients […]